NASDAQ$MURA
Mural Oncology Plc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Mural Oncology reported Q2 2025 a net loss of $52.8M, diluted EPS of $-0.94.
For Q2 2025, Mural Oncology reported net loss was $52.8M, diluted EPS was $-0.94. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Net loss $52.8M.
- Diluted EPS $-0.94.
- MD&A highlights operating priorities, liquidity, and sector risks.
Headline financials
Revenue & EPS history
Mural Oncology · Revenue · Quarterly
-$1
Forward guidance
Biopharma outlook emphasizes pipeline milestones, launch uptake, and R&D investment.
Tailwinds
- Franchise products and new indications.
- Cash runway for clinical and commercial programs.
Headwinds
- Patent cliffs and competitive entrants.
- Trial, regulatory, and reimbursement risk.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 7 quarterly earnings reports · overlaid with Q2 2025
-9.3%
Avg return
Earnings day
-9.4%
Avg return
5 days after
+5.1%
Avg return
30 days after
23%
3 / 13 earnings
Positive
+14.6%
Q4 2023
Best reaction
-61.6%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | -0.5% | -0.5% | — | |
| Q2 2025 | -20.2% | -30.3% | -9.2% | |
| Q1 2025 | -4.4% | -4.7% | -10.9% | |
| Q4 2024 | -61.6% | -65.0% | -31.3% | |
| Q3 2024 | -0.9% | -4.8% | +2.3% | |
| Q2 2024 | +1.0% | +4.5% | +0.6% | |
| Q1 2024 | +2.7% | +4.0% | -12.0% | |
| Q4 2023 | +14.6% | +13.2% | -16.7% | |
| Q1 2023 | -10.4% | -7.7% | +27.7% | |
| Q2 2023 | -10.4% | -7.7% | +27.7% | |
| Q3 2022 | -10.4% | -7.7% | +27.7% | |
| Q4 2022 | -10.4% | -7.7% | +27.7% | |
| Q3 2023 | -10.4% | -7.7% | +27.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro